NuCana (NCNA) Asset Writedowns and Impairment (2021 - 2024)
NuCana's (NCNA) quarterly Asset Writedowns and Impairment came in at -$42355.6 in Q4 2024, up 93.22% year-on-year from -$21921.4 in Q1 2024, and up 93.22% quarter-over-quarter from -$624299.4 in Q4 2023.
NuCana (NCNA) Asset Writedowns and Impairment (2021 - 2024) Analysis & Trends
NuCana has disclosed Asset Writedowns and Impairment across 4 years of filings, most recently posting -$42355.6 for Q4 2024.
- Asset Writedowns and Impairment for Q4 2024 came in at -$42355.6, up 93.22% year-over-year; the trailing twelve-month figure through Dec 2024 was -$4.8 million (changed N/A YoY), and the FY2024 annual result was -$42183.1, up 93.26% from the prior year.
- Asset Writedowns and Impairment came in at -$42355.6 for Q4 2024 at NuCana, up from -$624299.4 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of -$42355.6 in Q4 2024 to a low of -$3.8 million in Q4 2021.
- The 4-year median for Asset Writedowns and Impairment is -$483397.2 (2023), against an average of -$1.2 million.
- Across the five-year window, Asset Writedowns and Impairment sank 82.28% in 2023 and surged 93.22% in 2024, its largest moves.
- NuCana's Asset Writedowns and Impairment stood at -$3.8 million in 2021, then surged by 90.95% to -$342495.1 in 2022, then sank by 82.28% to -$624299.4 in 2023, then soared by 93.22% to -$42355.6 in 2024.
- The last three Asset Writedowns and Impairment figures came in at -$42355.6 (Q4 2024), -$624299.4 (Q4 2023), and -$342495.1 (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -42,355.56 |
| Dec 31, 2024 | -42,355.56 |
| Dec 31, 2023 | -624,299.40 |
| Dec 31, 2023 | -624,299.40 |
| Dec 31, 2022 | -342,495.07 |
| Dec 31, 2022 | -342,495.07 |
| Dec 31, 2021 | -3.79 Mn |
| Dec 31, 2021 | -3.79 Mn |